CA2484994C - Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes - Google Patents

Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Download PDF

Info

Publication number
CA2484994C
CA2484994C CA2484994A CA2484994A CA2484994C CA 2484994 C CA2484994 C CA 2484994C CA 2484994 A CA2484994 A CA 2484994A CA 2484994 A CA2484994 A CA 2484994A CA 2484994 C CA2484994 C CA 2484994C
Authority
CA
Canada
Prior art keywords
tgf
beta
seq
peptide
naturally occurring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2484994A
Other languages
English (en)
Other versions
CA2484994A1 (fr
Inventor
Jung San Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Original Assignee
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University filed Critical St Louis University
Publication of CA2484994A1 publication Critical patent/CA2484994A1/fr
Application granted granted Critical
Publication of CA2484994C publication Critical patent/CA2484994C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des procédés d'utilisation d'antagonistes peptidiques du TGF-bêta dans le but de faciliter la cicatrisation de plaies cutanées, notamment de brûlures, de lacérations et d'écorchures. L'administration à des plaies d'antagonistes peptidiques du TGF-bêta permet de réduire la formation de cicatrices, la contraction des plaies et le dépôt de composants matriciels extracellulaires, et elle permet également d'accroître les taux de ré-épithélialisation lors de la cicatrisation des plaies.
CA2484994A 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes Expired - Lifetime CA2484994C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13594602A 2002-04-29 2002-04-29
US10/135,946 2002-04-29
PCT/US2003/011437 WO2003093293A2 (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Publications (2)

Publication Number Publication Date
CA2484994A1 CA2484994A1 (fr) 2003-11-13
CA2484994C true CA2484994C (fr) 2016-06-14

Family

ID=29399231

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2484994A Expired - Lifetime CA2484994C (fr) 2002-04-29 2003-04-15 Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes

Country Status (4)

Country Link
EP (1) EP1534737A4 (fr)
AU (1) AU2003234734A1 (fr)
CA (1) CA2484994C (fr)
WO (1) WO2003093293A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
CA2588292C (fr) * 2004-12-01 2019-01-15 Health Protection Agency Conjugues proteiques non cytotoxiques
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
CN101652387A (zh) 2006-11-02 2010-02-17 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Ｔｇｆｐ－ｃａｐ 펩타이드 및 그의 용도
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
CN102099374B (zh) 2008-05-02 2016-06-08 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
WO2010033507A1 (fr) 2008-09-16 2010-03-25 St. Louis University Procédé d'amélioration de signalisation tgf-bêta
EP2420511B1 (fr) * 2009-04-14 2017-04-05 Caregen Co., Ltd. Peptide ayant une activite de facteur de croissance de transformation-beta et son procede de production
RU2012123145A (ru) 2009-11-05 2013-12-10 Проекто Де Биомедисина Сима, С.Л. Генный конструкт (варианты), вектор и рекомбинантный вирусный геном на его основе, вирион, их фармацевтическая композиция, способ in vitro экспрессии полинуклеотида в клетке печеночной природы, лекарственное средство, способ лечения заболевания печени (варианты), индуцируемый двунаправленный оператор-промотор
WO2012001196A2 (fr) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues
EP2407534A1 (fr) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Procédés et réactifs pour obtenir des particules virales actives du point de vue transcriptionnel et des virions recombinants
WO2013113755A1 (fr) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Réactifs et méthodes utilisables en vue du traitement de maladies par inhibition de la voie de signalisation calcineurine-nfat
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
EP2878674A1 (fr) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Épisomes stables sur la base des vecteurs lentiviraux non intégratifs
EP3089755A1 (fr) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia Vlp, procédés pour leur obtention et applications de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31

Also Published As

Publication number Publication date
EP1534737A4 (fr) 2007-10-31
WO2003093293A3 (fr) 2005-04-07
AU2003234734A8 (en) 2003-11-17
CA2484994A1 (fr) 2003-11-13
WO2003093293A2 (fr) 2003-11-13
AU2003234734A1 (en) 2003-11-17
EP1534737A2 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
CA2484994C (fr) Antagonistes peptidiques des elements de la famille du tgf-beta et utilisations therapeutiques de ces antagonistes
US20110008248A1 (en) Peptide Antagonists of TGF-Beta Family Members and Therapeutic Uses Thereof
US6500431B1 (en) Inhibitors of angiogenesis and tumor growth
EP0527787B1 (fr) Procede destine a predisposer les mammiferes a la regeneration acceleree des tissus
EP0494264B1 (fr) Inhibition de facteur de croissance a transformation afin d'empecher l'accumulation de matrice extracellulaire
CA2105652C (fr) Reduction de la cicatrisation en utilisant des anticorps a facteurs de croissance
US8691944B2 (en) Fibronectin polypeptides and methods of use
JPH08510443A (ja) 生物学的に活性なＴＧＦ−β１およびＴＧＦ−β２ペプチド
JPH0665680B2 (ja) 動物組織の修復
CA2859412C (fr) Distribution d'agents therapeutiques employant des segments polypeptidesliant un collagene bacterien
KR20100018107A (ko) 노화 방지 및 상처 치유를 위한 화합물
JPH07504650A (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
WO2000002916A2 (fr) COMPOSITIONS PEPTIDIQUES IMITANT L'ACTIVITE DE TGF-$g(b)
JPH09505555A (ja) ＴＧＦ−βの活性を刺激および阻害する方法および組成物
US7488719B1 (en) Wound and cutaneous injury healing with a nucleic acid encoding perlecan
US6500920B1 (en) Inhibitor of transforming growth factor β and A method of inhibiting the biological effects of transforming growth factor
EP0680334B1 (fr) Traitement d'ulceres gastro-intestinaux avec des morphogenes
WO1999055861A2 (fr) Compositions de muteine du facteur de croissance de fibroblastes et procedes d'utilisation associes
Huber et al. Activation of human platelet-derived latent transforming growth factor-β 1 by human glioblastoma cells. Comparison with proteolytic and glycosidic enzymes
ZA200104130B (en) Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof.
CA2106368A1 (fr) Methodes et compositions pour le traitement de la maladie angiogenique
AU7591000A (en) Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
US20100215583A1 (en) Cell nucleus-entering compositions
WO1998039436A2 (fr) Compositions de muteine du facteur de croissance des fibroblastes, et procedes d'utilisation de ces compositions
EP1049778B1 (fr) Proteines recombinees derivees de hgf et msp

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230417